Potential effects of icosapent ethyl on cardiovascular outcomes in cigarette smokers: REDUCE-IT smoking
Authors' conclusion
In REDUCE-IT, IPE treatment was associated with a reduced risk of CV events in current and former smokers to levels observed in never smokers.
Study context
- Population
- Statin-treated patients with elevated TG and CV risk, by smoking history (current, former, never smokers)4,913 current or former smokers
- Participants
- 8,179 patients
- Comparison
- Icosapent ethyl vs placebo, by smoking history
- Primary endpoint
- Composite of:
- CV death
- Non-fatal MI
- Non-fatal stroke
- Coronary revascularization
- Hospitalization for unstable angina
- Follow-up
- Median 4.9 years
Methodological detailspost hoc, multinational, double-blind
- Post hoc
- Multinational
- Double-blind
Primary result
As reported in the abstract
Primary composite endpoint, current and former smokers combined
IPE vs PlaceboEstimate (95% CI)P value
Time to first event
HR 0.77(0.68–0.87)
P < 0.0001Total events
rate ratio 0.71(0.61–0.82)
P < 0.0001- Benefit significant in current smokers (n = 1241)
- P = 0.04
- Benefit significant in former smokers (n = 3672)
- P = 0.005
Further findings
Estimated rate of first primary endpoint event
Key secondary composite endpoint, smokers
- Reduced with icosapent ethyl (IPE)
- P < 0.0001
CV death or non-fatal myocardial infarction (MI), current and former smokers
- Current smokers
- P = 0.04
- Former smokers
- P = 0.01
Fatal or non-fatal MI, current and former smokers
- Current smokers
- P = 0.009
- Former smokers
- P = 0.01
Original publication
Potential effects of icosapent ethyl on cardiovascular outcomes in cigarette smokers: REDUCE-IT smoking. Eur Heart J Cardiovasc Pharmacother. Published 11 August 2022. doi:10.
Summarised from the published abstract; every number is checked against it